Bevacizumab: New Option for Breast Cancer
REFERENCE: 5th European Breast Cancer Conference, Nice, 21st – 25th March 2006
Robin Zon, Michiana Hematology Oncology, South Bend, Indiana
Bevacizumab could be a new treatment option in metastatic breast cancer, according to a study reported at the 5th European Breast Cancer conference in Nice. Derek Thorne spoke to Robin Zon of Michiana Hematology Oncology, in South Bend Indiana, about the study findings.
Robin Zon, Michiana Hematology Oncology, South Bend, Indiana
Bevacizumab could be a new treatment option in metastatic breast cancer, according to a study reported at the 5th European Breast Cancer conference in Nice. Derek Thorne spoke to Robin Zon of Michiana Hematology Oncology, in South Bend Indiana, about the study findings.
Radiation for Young Patients with Prostate Cancer?
REFERENCE: Cancer, 2006, May 8
André Konski, Fox Chase Cancer Center, Philadelphia
Does age matter when selecting a treatment for patients with early stage prostate cancer? A study reported in the journal Cancer suggests it may not. André Konski told Derek Thorne about a retrospective study carried out at the Fox Chase Cancer Center in Philadelphia.
André Konski, Fox Chase Cancer Center, Philadelphia
Does age matter when selecting a treatment for patients with early stage prostate cancer? A study reported in the journal Cancer suggests it may not. André Konski told Derek Thorne about a retrospective study carried out at the Fox Chase Cancer Center in Philadelphia.
Better Combine Chemotherapy with Radiation for Hodgkins’ Disease
REFERENCE: Journal of Clinical Oncology 2006; 24:605
Bridget Koontz, Duke University Medical Center, Durham
In early stage Hodgkin’s Disease many doctors are now using combined modality therapy, involving chemotherapy and a lower dose of radiation. Bus is it any safer than radiation alone? A retrospective study from Duke University Medical Center suggests that it is. Derek Thorne got the details from Bridget Koontz.
Bridget Koontz, Duke University Medical Center, Durham
In early stage Hodgkin’s Disease many doctors are now using combined modality therapy, involving chemotherapy and a lower dose of radiation. Bus is it any safer than radiation alone? A retrospective study from Duke University Medical Center suggests that it is. Derek Thorne got the details from Bridget Koontz.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.